News & Updates

Induction chemotherapy before CRT ups survival in locally advanced cervical cancer

Induction chemotherapy followed by chemoradiotherapy (CRT) significantly improves progression-free survival (PFS) and overall survival (OS) in patients with locally advanced cervical cancer compared with standard CRT alone, according to the INTERLACE trial presented at ESMO 2023.

Datopotamab deruxtecan shows PFS benefit in patients with HR+/HER2- breast cancer

Treatment with datopotamab deruxtecan (Dato-DXd), an investigational TROP2*-directed antibody-drug conjugate, significantly improves progression-free survival (PFS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, according to the TROPION-Breast01 trial presented at ESMO 2023.

Simvastatin not superior to standard of care critically ill patients with COVID-19

In the treatment of critically ill patients with COVID-19, simvastatin is not necessarily better than standard of care in terms of improving organ support-free days and death outcomes, according to a study.

Original New Drug Application Approvals by US FDA (16-31 October 2023)

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A closer look at ceftazidime-avibactam in real-world settings

Antibiotic misuse and overuse fuel mutations in bacteria, leading to drug-resistant “superbugs,” with terrifying aftermath. Without intervention, antimicrobial resistance could cause 10 million deaths annually by 2050.

Every year, from November 18–24, the World Antimicrobial Awareness Week highlights these risks and promotes innovative treatments, enhanced surveillance, and best-practice sharing among clinicians. This article offers insights on the use of the fixed-dose combination antibiotic ceftazidime-avibactam in daily hospital settings.